Abstract

Respiratory syncytial virus (RSV) is a common respiratory tract infection that causes bronchiolitis and pneumonia in infants and children. It is the leading cause of hospitalization of infants in the United States. Nirsevimab is a long-acting monoclonal antibody recommended for the prevention of severe disease in all infants under 8 months of age and certain high-risk toddlers. Recent data demonstrate a 90% protection against hospitalization from severe RSV disease for infants who received nirsevimab in their first RSV season. Providers should understand the mechanism of action, safety, efficacy, and prescribing recommendations for nirsevimab, especially when confronted with caregivers who are hesitant about medications and vaccines. Special circumstances may require nuanced prescribing of nirsevimab to safely provide optimal protection. In these circumstances, and during drug shortages, a lens of health equity should be used to protect the highest risk populations.

Full Text

Published Version

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.